ESTRO Annual Report 2019

RESEARCH

The scientific engagement policy supports, facilitates, contributes to and/or drives research projects in line with the Society’s vision and relevance to its members. The scope of ESTRO involvement varies with the research topic, the type of research activity and the level of support requested. On the next pages are explanations of research activities in which ESTRO was involved in 2019. 1. EORTC-ESTRO Radiation Infrastructure for Europe (E 2 -RADIatE) The EORTC and ESTRO partnership endeavours to use this overarching platform to address the needs of the radiation oncology community in understanding the effectiveness of new and innovative treatments to improve the quality of life and survival of cancer patients.

E 2 -RADIatE is a joint ESTRO-European Organisation for the Research and Treatment of Cancer (EORTC) project that aims to develop a holistic database and infrastructure for radiation oncology research, in line with the ESTRO Vision 2030 and with the strategy of EORTC to conduct multidisciplinary research that covers all aspects of cancer management. The E 2 -RADIatEplatform is built tohost prospective data registries of “real-world” data on patients treated through radiotherapy. Radiation therapy suffers from a lack of collective knowledge on how treatments affect patients’ survival rates and qualities of life. For some cancers and indications, information is available through clinical trials, but formal data collection and data sharing is rather random especially with new treatments and techniques, and this may result in patients not receiving the best treatment for their cancer. The platformwill link diagnostic, radiation imaging, and treatment data to clinical outcomes for several cancers, thereby facilitating the analysis of new clinical indications treated by radiotherapy and the monitoring of new radiation techniques and technologies.

OligoCare is the first cohort hosted on the E 2 - RADIatE platform and will collect data on the treatment of oligometastatic disease in lung, breast, prostate and colorectal cancer. The objective of this data collection is to identify what factors (cancer, organ affected, staging, treatment) have an impact on overall survival of patients who develop oligometastatic disease at some point. By the end of 2019, nine sites in six European countries are recruiting and eight additional sites have been activated. In 2020, another 53 sites in 14 different countries will be activated. The aim is to have as many centres as possible engaging in this recruitment platform, for this cohort and/or for the many other cohorts planned for future years.

Formore details on activities of the E2-RADIatE please visit: www.estro.org/Science/Activities/ E2RADIATE

34